SCHEMBL15901247

SCHEMBL15901247

CCCCn1c2nc(=O)n(CCCI)c(=O)c-2nc2cc(C)c(C)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.44
▸ ALDH1A1 P00352 8/20 0.44
▸ HPGD P15428 6/20 0.44
▸ GAA P10253 3/20 0.44
▸ GLA P06280 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ THRB P10828 1/20 0.41
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ MAPT P10636 3/20 0.40
▸ USP2 O75604 3/20 0.40
▸ RXFP1 Q9HBX9 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ LMNA P02545 3/20 0.39
▸ SIRT2 Q8IXJ6 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16479714 0.94 KDM4E (0.46) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL8510100 0.89 KDM4E (0.42) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL14377795 0.86 KDM4E (0.41) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL16476450 0.86 KDM4E (0.41) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL15908096 0.86 KDM4E (0.41) KDM4EALDH1A1HPGDGAAGLA
Bromide SCHEMBL15901676 0.85 KDM4E (0.40) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL16476444 0.85 KDM4E (0.40) KDM4EALDH1A1HPGDGAAGLA
Iodide SCHEMBL29959754 0.84 KDM4E (0.39) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL14378204 0.84 KDM4E (0.39) KDM4EALDH1A1HPGDGAAGLA
Iodide SCHEMBL17254516 0.83 KDM4E (0.38) KDM4EALDH1A1HPGDGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3586632-B1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR PRODUCING SAME AND USE OF SAME TRIOPTOTEC GMBH (DE) 2022-09-28 — — EP disclosed
EP-3838902-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR PRODUCING SAME AND USE OF SAME TriOptoTec GmbH (DE) 2021-06-23 — — EP disclosed
EP-2723742-B1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH (DE) 2020-11-18 — — EP disclosed
EP-2723743-B1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH (DE) 2019-08-14 — — EP disclosed
US-9745302-B2 10H-benzo[g]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof TRIOPTOTEC GMBH (DE) 2017-08-29 — — US disclosed
US-9745302-B2 10H-benzo[g]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof TRIOPTOTEC GMBH (DE) 2017-08-29 — — US disclosed
US-9745302-B2 10H-benzo[g]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof TRIOPTOTEC GMBH (DE) 2017-08-29 — — US disclosed
US-20160176877-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH 2016-06-23 — — US disclosed
US-20160176877-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH 2016-06-23 — — US disclosed
US-20160176877-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH 2016-06-23 — — US disclosed
US-9241995-B2 10H-benzo[G]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof TRIOPTOTEC GMBH (DE) 2016-01-26 — — US disclosed
US-9241995-B2 10H-benzo[G]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof TRIOPTOTEC GMBH (DE) 2016-01-26 — — US disclosed
US-9185913-B2 10H-benzo[g]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof TRIOPTOTEC GMBH (DE) 2015-11-17 — — US disclosed
US-9185913-B2 10H-benzo[g]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof TRIOPTOTEC GMBH (DE) 2015-11-17 — — US disclosed
US-9185913-B2 10H-benzo[g]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof TRIOPTOTEC GMBH (DE) 2015-11-17 — — US disclosed
US-20140212459-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH (DE) 2014-07-31 — — US disclosed
US-20140212459-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH (DE) 2014-07-31 — — US disclosed
US-20140212459-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH (DE) 2014-07-31 — — US disclosed
US-20140200220-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH (DE) 2014-07-17 — — US disclosed
US-20140200220-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH (DE) 2014-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200220-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF DHPS, DOHH, DPYD KDM4E 495/4885ALDH1A1 1162/4885HPGD 15/4885
US-20160176877-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF DHPS, DOHH, PAH KDM4E 376/4885ALDH1A1 1089/4885HPGD 13/4885
US-20140212459-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF DHPS, DOHH, PAH KDM4E 376/4885ALDH1A1 1089/4885HPGD 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback